Wang JL - Search Results

1

A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma.

Wang JL, Tang LS, Zhong X, Wang Y, Feng YJ, Zhang Y, Liu JY. Wang JL, et al. Among authors: wang y. Front Immunol. 2024 Jun 14;15:1405146. doi: 10.3389/fimmu.2024.1405146. eCollection 2024. Front Immunol. 2024. PMID: 38947338 Free PMC article.

2

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.

Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, Ma X. Tang L, et al. Front Immunol. 2021 Dec 21;12:800879. doi: 10.3389/fimmu.2021.800879. eCollection 2021. Front Immunol. 2021. PMID: 34992611 Free PMC article. Review.

3

Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study.

Zhou YW, Wang JL, Li QF, He YL, Li LJ, Liu RZ, Chen Y, Zhang S, Qiu M, Liu JY. Zhou YW, et al. Among authors: wang jl. Therap Adv Gastroenterol. 2022 May 18;15:17562848221098246. doi: 10.1177/17562848221098246. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 35601804 Free PMC article.

4

Clinical characteristics and prognostic factors of anal adenocarcinoma: a nomogram development based on SEER database and validation in the WCH database.

Zhou YW, Wei GX, Tang LS, Hao YT, Wang JL, Qiu M. Zhou YW, et al. Among authors: wang jl. Int J Colorectal Dis. 2022 Aug;37(8):1773-1784. doi: 10.1007/s00384-022-04211-w. Epub 2022 Jul 4. Int J Colorectal Dis. 2022. PMID: 35781608

5

Personalised neoantigen-based therapy in colorectal cancer.

Zhu YJ, Li X, Chen TT, Wang JX, Zhou YX, Mu XL, Du Y, Wang JL, Tang J, Liu JY. Zhu YJ, et al. Among authors: wang jx, wang jl. Clin Transl Med. 2023 Nov;13(11):e1461. doi: 10.1002/ctm2.1461. Clin Transl Med. 2023. PMID: 37921274 Free PMC article. Review.

6

Epidemiology, site-specific characteristics and survival of carcinosarcoma: a retrospective study based on SEER database.

Tang LS, Zhou YW, Wang JL, Zhang GX, Xu CH, Liu JY, Qiu M. Tang LS, et al. Among authors: wang jl. BMJ Open. 2023 Dec 14;13(12):e077974. doi: 10.1136/bmjopen-2023-077974. BMJ Open. 2023. PMID: 38101828 Free PMC article.

7

Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.

Zhou YX, Wang JL, Mu XL, Zhu YJ, Chen Y, Liu JY. Zhou YX, et al. Among authors: wang jl. Aging (Albany NY). 2023 Dec 22;15(24):15473-15488. doi: 10.18632/aging.205382. Epub 2023 Dec 22. Aging (Albany NY). 2023. PMID: 38147019 Free PMC article.

8

Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget's disease with Her-2 overexpression.

Wang JL, Meng WJ, Hu N, Liu JY. Wang JL, et al. Front Immunol. 2024 Jun 26;15:1349033. doi: 10.3389/fimmu.2024.1349033. eCollection 2024. Front Immunol. 2024. PMID: 38989283 Free PMC article.

9

Meng WJ, Guo JM, Huang L, Zhang YY, Zhu YT, Tang LS, Wang JL, Li HS, Liu JY. Meng WJ, et al. Among authors: wang jl. Bioengineering (Basel). 2024 Sep 5;11(9):893. doi: 10.3390/bioengineering11090893. Bioengineering (Basel). 2024. PMID: 39329635 Free PMC article.

10

Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third-line therapy in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study.

Zhou Y, Xu Q, Wang J, Leng WB, Cao P, Chen Y, Luo DY, Qiu M, Liu J. Zhou Y, et al. J Evid Based Med. 2024 Sep;17(3):667-674. doi: 10.1111/jebm.12652. Epub 2024 Sep 26. J Evid Based Med. 2024. PMID: 39327543

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,337 results

Search Page

Filters